XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition
 3 Months Ended
Mar. 31, 2021
Revenue Recognition [Abstract]  
Revenue Recognition

8. Revenue Recognition

Our product revenue, net consisted of the following:

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2021

 

 

2020

 

HEPLISAV-B

 

$

8,303

 

 

$

10,514

 

CpG 1018

 

 

74,582

 

 

 

-

 

Total

 

$

82,885

 

 

$

10,514

 

 

All of our HEPLISAV-B sales were in the U.S. For the three months ended March 31, 2021 and 2020, our three largest Customers collectively represented approximately 75% and 68% of our HEPLISAV-B product revenue, respectively.

All of our CpG 1018 sales were outside the U.S. For the three months ended March 31, 2021, one customer represented approximately 87% of our CpG 1018 product revenue.

The following table summarizes balances and activity in HEPLISAV-B product revenue allowance and reserve categories for the three months ended March 31, 2021 (in thousands):

 

 

 

Balance at

Beginning

of Period

 

 

Provisions

related to

current

period sales

 

 

Credit or

payments

made during

the period

 

 

Balance

at End of

Period

 

Three months ended March 31, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable reserves(1)

 

$

2,836

 

 

$

1,962

 

 

$

(2,469

)

 

$

2,329

 

Revenue reserve accruals(2)

 

$

6,040

 

 

$

1,641

 

 

$

(1,533

)

 

$

6,148

 

 

(1)

Reserves are for chargebacks, discounts and other fees.

(2)

Accruals are for returns, rebates and other fees.